IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner of Patents **BOX PATENT APPLICATION** Washington, D.C. 20231



TRANSMITTAL FOR A NEWLY EXECUTED ORIGINAL APPLICATION UNDER 37 C.F.R. §1.53(b)

This is a request for filing a patent application under 37 C.F.R. §1.53(b) for:

	ventor: Dario C. ALTIERI, Robert M. WEISS, Shannon D. SMITH, Marcia A. HEELER, and Janet PLESCIA
Fo:	r: DETECTION OF SURVIVIN IN THE BIOLGICAL FLUIDS OF CANCER PATIENTS
1.	This is a new 🗷 Utility 🗌 Design 🔲 Plant patent application.
2.	The papers enclosed to obtain a filing date are as follows:
	Pages of Specification including Title Page Pages of Claims Page of Abstract Sheets of drawings containing 4 Figures The enclosed drawings are photographs, and there is also attached a PETITION TO ACCEPT PHOTOGRAPH(S) AS DRAWING(S)
3.	Combined Declaration and Power of Attorney
	Enclosed and is executed by all inventors Not Enclosed. This application is being filed under the provisions of 37 C.F.R. §1.53(f). Applicant(s) await notification from the Patent and Trademark Office of the time set for filing the Declaration and paying the filing fees.

	ď	
	7	ľ
•		ì
		•
111111	I I I I I I I I I I I I I I I I I I I	:
	-	,
=		
7	-,-	•
=	=	=
5	_	_
•		
=	i	::
=	=	
Ξ	Ξ	1
=	**	ä
H	Ē	
-	=	*****
2	1111	*
Ē		
44115	-	
111111	-	=
	_	
12001	THE HOUSE	1
H	=	
11111	ffright.	

4.	Language				
		of the MP	cation is being f EP. Applicant(s) await notificati	e with 37 C.F.R. §1.52(d) and §608.03 on from the Patent and Trademark English translation and the processing
5.	Assignment				
	□ ⊠	An assignment of the invention to and a PTO Form-1595, Recordation Form Cover Sheet, are enclosed. An assignment will be filed at a later date.			
6.	Priority - foreign applications unde	application or 35 U.S.C	as under 35 U.S.0 . §365(a) design	C. §119(a)-(d) or ating at least one	§365(b) or PCT international country other than the U.S.
	Priority of	the follow	ing foreign appl	ication is claimed	1 :
	Country		Applica	tion No.	Filed
		···			
-	Certified copy: is attached. will follow.				
7.	Priority based on	provisional	l application(s) -	35 U.S.C. §119((e)
	Priority of	the followi	ng provisional a	pplication(s) is c	laimed:
		cation No.			Filed
	60/2	260,898			January 12, 2001
	A. Relate Back - 35 U.S.C. §119(e) Amend the specification by inserting before the first line the sentence: "This application claims priority of copending provisional application(s) No filed on"				
8.	Small entity st	tatus			
	×	Applicant(s) hereby assert(s) small entity sta	atus under 37 C.F.R. § 1.27.

9. Fee Calculation (37 C.F.R. §1.16)

	Number Filed	Number Extra	at Rate of	Basic Fee Utility \$740.00 Design \$330.00	
			BASIC FEI		
Total Claims (37 C.F.R. §1.16(c))					
Independent Claims (37 C.F.R. §1.16(b))					
Multiple dependent claim(s), if any (37 C.F.R. §1.16(d))					
SUB-TOTAL =					
Reduction by 1/2 for filing by a small entity					
TOTAL FILING FEE =					

1	0.	Fee	Payment

	×	Not Enclosed. NO FEE IS BEING PAID BY CHECK OR DEPOSIT ACCOUNT AT THIS TIME. This application is being filed under the provisions of 37 C.F.R. §1.53(f). Applicant(s) await notification from the Patent and Trademark Office of the time set for filing the Declaration and paying the filing fees. Enclosed. A check in the amount of \$ representing the basic filing fee of \$740.00 and an assignment recording fee of \$40.00 is enclosed
11.		Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. §1.136(a)(3).

12.	Additional papers enclosed:		
		Preliminary Amendment	
		Information Disclosure Statement	
		Form PTO-1449, document included	
	×	Statement Accompanying Sequence Listing	
	×	Submission of "Sequence Listing", computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence	

Please accord this application an application number and filing date.

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

Dated: January 11, 2002 **Customer No. 09629** MORGAN, LEWIS & BOCKIUS LLP 1800 M Street, N.W. Washington, D.C. 20036 (202) 467-7000-

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Dario C. ALTIERI et al.))
Application No.: Unassigned (Based on US Provisional Application 60/260,898) Filed: January 11, 2002) Group Art Unit: Unassigned) Examiner: Unassigned
For: Detection of Survivin in the Biological Fluids of Cancer Patients)))

Box Sequence

Commissioner for Patents Washington, D.C. 20231

STATEMENT ACCOMPANYING SEQUENCE LISTING

Dear Sir:

The undersigned hereby states upon information and belief that the information recorded on the diskette submitted concurrently herewith is identical to the written Sequence Listing submitted herewith.

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

Dated: January 11, 2002

Rachel B. Kapust

Customer No. 09629 MORGAN, LEWIS & BOCKIUS LLP

1800 M Street, NW Washington, D.C. 20036

Tel: 202-467-7000; Fax: 202-467-7258